Tonix Pharmaceuticals (NASDAQ:TNXP) Posts Quarterly Earnings Results, Beats Expectations By $1.80 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its quarterly earnings data on Tuesday. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80, Zacks reports. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%.

Tonix Pharmaceuticals Stock Down 2.8 %

NASDAQ:TNXP traded down $0.00 on Thursday, hitting $0.14. 4,763,976 shares of the company’s stock were exchanged, compared to its average volume of 10,126,823. The company has a market cap of $18.85 million, a P/E ratio of 0.00 and a beta of 2.06. The firm has a 50-day moving average price of $0.15 and a 200-day moving average price of $1.49. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $22.14.

Wall Street Analysts Forecast Growth

TNXP has been the topic of a number of research reports. Alliance Global Partners boosted their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 22nd. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Wednesday. They issued a “sell” rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.